Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDQ443 phase Ib/II study in KRAS G12C-mutant advanced solid tumors
jRCT2031200379Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of opnurasib, batoprotafib and tislelizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (4 arms), sponsored by Novartis. Primary endpoints: Incidence and severity of dose-limiting toxicities, Incidence and severity of adverse events and serious adverse events and 3 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
opnurasibbatoprotafibtislelizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031200379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200379.